Cefepime–taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and <i>Pseudomonas aeruginosa</i>: GEARS global surveillance programme 2018–22
Cefepime-taniborbactam exhibited potent in vitro activity against Enterobacterales and P. aeruginosa, and inhibited most carbapenem-resistant isolates, including those carrying serine carbapenemases or NDM/VIM MBLs.
Authors
- David A. Six (ORCID: https://orcid.org/0000-0002-9013-1711)
- Tsuyoshi Uehara (ORCID: https://orcid.org/0000-0001-6994-4286)
- Daniel C. Pevear
- James A. Karlowsky (ORCID: https://orcid.org/0000-0002-1939-464X)
- Denis M. Daigle (ORCID: https://orcid.org/0000-0001-9287-2997)
- Meredith Hackel (ORCID: https://orcid.org/0000-0003-3339-2701)
- Greg Moeck (ORCID: https://orcid.org/0000-0001-7827-7227)
- Mark G. Wise (ORCID: https://orcid.org/0000-0001-7356-1851)
- Daniel F. Sahm
Institutions
- American Veterinary Medical Association (US)
- VenatoRx Pharmaceuticals (United States) (US)
- University of Manitoba (CA)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2024-09-04
- DOI
- https://doi.org/10.1093/jac/dkae329
- Citations
- 21
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 3.58
Funders
- U.S. Department of Health and Human Services
- Wellcome Trust
- Department of Health and Human Services, State Government of Victoria
- National Institutes of Health
- Biomedical Advanced Research and Development Authority
- National Institute of Allergy and Infectious Diseases